US · CUPR
Cuprina Holdings (Cayman) Limited Class A Ordinary Shares
- Sector
- Healthcare · Biotechnology
- Headquarters
- Singapore 169201
- Website
- cuprina.com.sg
Price · as of 2024-12-31
$0.25
Market cap 7.84M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | |||||
| 2021 | |||||
| 2022 | |||||
| 2023 | |||||
| 2024 |
AI valuation
Our deep-learning model estimates Cuprina Holdings (Cayman) Limited Class A Ordinary Shares's (CUPR) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- $0.25
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| CUPR | Cuprina Holdings (Cayman)… | $0.25 | 7.84M | — | — | — | — | — | — | — | — | — | — | -6.26% | -3404.85% | -3229.52% | 42.42% | 46.14% | -93.71% | -0.06 | -44.22 | 0.27 | 0.04 | -0.10 | 3922.00% | -5205.00% | -2191.00% | — | -0.20 | 35.27% | — | 0.00% | — | — | — | — | — |
| ASBP | Aspire Biopharma Holdings… | $1.39 | 4.81M | — | — | — | — | -866.02 | -736.56 | — | -97.51 | — | -736.56 | 0.00% | — | — | -14.52% | -32.00% | -13.01% | -0.82 | 3.46 | 0.09 | 0.02 | -0.11 | -76087.00% | — | -5940.00% | -0.02% | -0.16 | -2.75% | 0.00% | 0.00% | 1.21% | -367.68 | -4282.42 | — | 295.56 |
| BCTX | BriaCell Therapeutics Cor… | $3.82 | 7.2M | — | — | — | — | -0.64 | 0.95 | — | 0.03 | -1.44 | 0.96 | 0.00% | — | — | -343.04% | 1683.01% | -192.49% | 0.00 | -735.71 | 5.01 | 4.63 | 0.39 | 4450.00% | — | 1632.00% | -167.26% | -7.14 | 1742.76% | 0.00% | 0.00% | 56.64% | 0.03 | 0.03 | — | -8.16 |
| CRIS | Curis, Inc. | $1.14 | 15.61M | +342% | +2% | — | — | -0.42 | -3.06 | 1.68 | -0.03 | — | -1.23 | 99.10% | -408.34% | -397.77% | -634.71% | 156.53% | -73.20% | -0.49 | -72.43 | 1.39 | 1.23 | 0.40 | -2321.00% | 883.00% | 294.00% | -215.59% | -2.08 | 139.03% | 0.00% | 0.00% | 0.00% | -0.03 | -0.03 | 0.12 | -44.91 |
| CURX | Curanex Pharmaceuticals I… | $0.45 | 12.76M | — | — | — | — | — | — | — | — | — | — | 0.00% | — | — | -128.32% | -214.62% | -122.07% | 0.00 | — | 35.54 | 10.22 | 0.51 | 175714.00% | — | 46287500.00% | — | -38.12 | -326.62% | — | 0.00% | — | — | — | — | — |
| ENTO | Entero Therapeutics, Inc. | $2.85 | 13.58M | — | — | — | — | -0.43 | 0.13 | — | -491.36 | — | 0.14 | 0.00% | — | — | -58.82% | -0.05% | -39.13% | 0.00 | — | 3.03 | 0.01 | 1.47 | -8880.00% | — | -2842.00% | -119.84% | -0.33 | -31.51% | 0.00% | 0.00% | 0.00% | -490.90 | -0.83 | — | -2.37 |
| HOTH | Hoth Therapeutics, Inc. | $1.01 | 13.39M | — | — | — | — | -0.85 | 1.01 | — | -2.17 | — | 1.01 | 0.00% | — | — | -99.75% | -9559.27% | -91.21% | 0.00 | — | 9.20 | 8.52 | -258.29 | -4435.00% | — | -1739.00% | -100.42% | -8.40 | -8119.72% | 0.00% | 0.00% | 0.00% | 0.01 | 0.01 | — | -8.42 |
| PALI | Palisade Bio, Inc. | $1.77 | 263.74M | +38% | — | — | — | -0.08 | 0.16 | — | 0.59 | — | 0.16 | 0.00% | — | — | -153.55% | 1021.24% | -115.82% | 0.02 | -1238.25 | 3.24 | 3.04 | 0.67 | -6227.00% | -10000.00% | 948.00% | -1013.04% | -3.77 | 838.01% | 0.00% | 0.00% | 0.00% | 0.57 | 0.69 | — | -20.99 |
| PCSA | Processa Pharmaceuticals,… | $2.17 | 4.92M | — | — | — | — | -0.12 | 0.87 | — | -0.03 | — | 0.87 | 0.00% | — | — | -354.51% | -2381.97% | -262.87% | 0.04 | — | 1.22 | 0.78 | 0.09 | -5436.00% | — | 3945.00% | -761.08% | -7.34 | -2223.27% | 0.00% | 0.00% | 1.08% | -0.03 | -0.03 | — | -49.42 |
| PULM | Pulmatrix, Inc. | $2.99 | 10.92M | +6,325% | — | — | — | -1.34 | 1.81 | — | -0.55 | — | 1.81 | 0.00% | — | — | -80.93% | 1213.38% | -73.31% | 0.00 | — | 12.55 | 12.43 | 0.79 | -4618.00% | -10000.00% | -5112.00% | -78.71% | -16.51 | 1275.35% | 0.00% | 0.00% | 0.00% | -0.54 | -0.52 | — | -92.69 |
| SYBX | Synlogic, Inc. | $0.62 | 7.25M | +6,671% | -15% | — | +26,878% | -0.69 | 1.26 | 2004.75 | 0.13 | — | 1.26 | 100.00% | -511875.00% | -291987.50% | -84.32% | -1348.15% | -48.98% | 0.00 | — | 2.80 | 2.67 | 0.85 | -7821.00% | -9976.00% | -3889.00% | -197.48% | -4.47 | -1042.70% | 0.00% | 0.00% | 75.91% | 0.07 | 0.09 | -352.75 | -35.87 |
About Cuprina Holdings (Cayman) Limited Class A Ordinary Shares
Cuprina Holdings (Cayman) Limited is a Singapore-based biomedical and biotechnology company dedicated to developing and commercializing innovative products for managing chronic wounds. The company manufactures and distributes medical-grade sterile blowfly larvae bio-dressing products under the MEDIFLY brand, used as a biological debridement tool for chronic wounds. Additionally, Cuprina operates in the health and beauty sectors, offering cosmeceutical products.
- CEO
- Yong Qi Quek
- Employees
- 15
- Beta
- 6.20
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $0.25) − 1 = — (DCF, example).